Rituximab in Patients with High Risk Lymphoma

A Randomized Phase II study of Brentuximab Vedotin and Crizotinib in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)

February 21, 2018

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: ANHL12P1

    Protocol Abbrev: ANHL12P1

    Principal Investigator: Vincent F. Giusti, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Martin, Rebecca, ARNP; Pope, Michele ARNP; Smith, Amy MD; Story, Allison ARNP; Sullivan Darden, Kelly ARNP; Sutphin, Robert MD; Wieber, Laura ARNP; Levy, Alejandro MD

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: ANHL12P1

    Treatment: Drug: Brentuximab Vedotin; Drug: Crizotinib; Other: Laboratory Biomarker Analysis; Drug: Chemotherapy (multiple); Drug: Dexamethasone

    Applicable Disease Sites: Lymphoma Leukemia

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT01979536

  • Objective

    This trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients

  • Key Eligibility

    up to 21 Years